Implementing VTE Prevention in Ambulatory Cancer Care

NCT07292376 | Enrolling By Invitation

• 1 other identifier: FP00005110
• Study Type: interventional
• Target: 25
• Locations: 1 country
• Sites: 1

Brief Summary

assess effectiveness of a , compared with usual care, to assess The goal of this study is to learn if a modified clinical program can improve adherence to guideline recommendations for prevention of venous thromboembolism in ambulatory patients with cancer. The main question\[s\] it aims to answer are: Does the modified program improve number of ambulatory oncology patients starting systemic treatment getting VTE risk-assessment? Does the modified program improve the number of patients receiving appropriate preventative anticoagulation? Researchers will compare to usual care (no clinical program). Participant clinicians will be asked to

• receive education about VTE prevention recommendations
• carry out risk assessment, anticoagulation discussions, and document the results Participant patients will receive care from clinicians participating in the study as part of their cancer care.

Conditions

Venous Thromboembolism; Neoplasms

Outcome Measures

Primary Outcomes (1)

• Documented VTE risk assessment

  Proportion of new patients who have documented VTE risk assessment

  30 days after new patient appointment

Secondary Outcomes (1)

• Appropriate thromboprophylaxis

  30 days after new patient appointment

Study Arms (1)

Clinical program

OTHER

Other: Clinical program

Interventions

Clinical program OTHER

Revised Vermont Model clinical program, including standardized education and training for oncology care team, clinical decision support and revised workflow for VTE risk assessment and thromboprophylaxis.

Clinical program

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Clinicians: practicing oncologist at study clinic site (UVMMC)
• Patients: diagnosis of cancer; starting new systemic cancer-directed therapy at a study clinic site under the direction of the enrolled clinician

You may not qualify if:

• none

Sponsors & Collaborators

• University of Vermont: lead

Study Sites (1)

Vermont Health

Burlington, Vermont, 05405, United States

Location

MeSH Terms

Conditions

Venous Thromboembolism; Neoplasms

Condition Hierarchy (Ancestors)

Thromboembolism; Embolism and Thrombosis; Vascular Diseases; Cardiovascular Diseases

Study Officials

• Karlyn Martin, MD

  University of Vermont

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor of Medicine

Study Record Dates

• First Submitted: December 5, 2025
• First Posted: December 18, 2025
• Study Start: October 1, 2025
• Primary Completion: April 30, 2026
• Study Completion (Estimated): July 30, 2026
• Last Updated: December 18, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)